Inclusion Criteria:

          -  Age ≥18 years.

          -  Has pancreatic ductal adenocarcinoma

          -  Has resectable disease at the time of diagnosis

          -  Has not received any systemic therapy for pancreatic ductal adenocarcinoma

          -  Has stage ≤ IIb disease at time of diagnosis and enrollment

          -  Elevated tumor marker, CA (carbohydrate antigen) 19-9 >200

          -  ECOG performance status 0 or 1

          -  Patient must have adequate organ function defined by the study-specified laboratory
             tests.

          -  Must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

        Patients who have received any prior chemotherapy, radiotherapy or investigational agents
        for pancreatic cancer.

          -  Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell
             receptor (e.g., CTLA-4, OX 40, CD137).

          -  Has received prior therapy with FAK inhibitor.

          -  Woman who are pregnant or breastfeeding.

          -  Have received a live vaccine or live-attenuated vaccine within 30 days prior to study
             drug.

          -  Is currently or has participated in another investigational study within 4 weeks prior
             to receiving study drug.

          -  History or current use of immunosuppressive medications within 7 days prior to study
             medications.

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 2 years or that is expected to require active treatment within two
             years.

          -  Has active autoimmune disease that has required systemic treatment in the past 2
             years.

          -  Has a history of (non-infectious) pneumonitis/interstitial lung disease or current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Infection with HIV or hepatitis B or C.

          -  Patient with uncontrolled intercurrent illness including, but not limited to,
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Known allergy or hypersensitivity to the study drugs.

          -  Received any growth factors including, but not limited to, granulocyte-colony
             stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug
             administration.

          -  Has history of any organ transplant, including corneal transplants.